# GlucoShield — Phase 7A Multimodal Data & Feature Feasibility Audit
**Document ID:** `GLUCOSHIELD-RPT-PHASE7A-AUDIT-001`  
**Timestamp:** 2026-08-28T15:56:00 Local Time  
**Author:** Lead Deep Learning & Physiological Systems Engineer  
**Status:** **INSPECTION & RESEARCH AUDIT COMPLETE (V1 FROZEN)**  

---

## 1. Executive Summary & Audit Objectives

Phase 7A performs a comprehensive, research-grade inspection of the **GlucoShield V1 data architecture** and evaluates the feasibility, scientific validity, and compatibility of candidate multimodal features for **GlucoShield V2**.

### Invariant Preservation Guarantee:
* **GlucoShield V1 is PERMANENTLY LOCKED & FROZEN:** Dataset v1.0 ($N=28,447$ sequences, 112 patients), all models (`glucoshield_hybrid_best.pt`, `glucoshield_neural_best.pt`), baseline models, predictions, and Phase 6 evaluation benchmarks remain bitwise intact and reproducible.
* **Phase 7A is PLANNING ONLY:** Zero models are retrained, zero data is altered, and no synthetic/chimera patient records are created.

---

## 2. Deep Inspection of Current GlucoShield V1 Data

### A. Provenance & Structure
* **Source Cohort:** Shanghai Clinical Diabetes Dataset (ShanghaiT1D & ShanghaiT2D, published in *Nature Scientific Data*).
* **Cohort Size:** **112 unique clinical patients** (12 Type 1 Diabetes, 100 Type 2 Diabetes).
* **Sequences:** **28,447 total 29-hour sliding windows** ($19,749$ Train / $4,585$ Val / $4,113$ Test).
* **Sampling Resolution:** Uniform **15-minute grid** ($96\text{ input steps} = 24\text{ hours}$, $20\text{ forecast steps} = 5\text{ hours}$).

### B. Current 22 Dynamic Features (Every 15 min)
1. `glucose` (mg/dL) — Continuous interstitial CGM sensor telemetry.
2. `glucose_velocity` ($\Delta G / 15\text{m}$) — 1st-order rate-of-change momentum.
3. `glucose_accel` ($\Delta^2 G / 15\text{m}^2$) — 2nd-order acceleration.
4. `glucose_roll_mean_1h` — 4-step rolling glucose mean.
5. `glucose_roll_std_1h` — 4-step short-term glycemic volatility.
6. `glucose_roll_min_1h` — 4-step local minimum.
7. `glucose_roll_max_1h` — 4-step local maximum.
8. `glucose_roll_mean_3h` — 12-step intermediate trend.
9. `glucose_roll_std_3h` — 12-step intermediate volatility.
10. `glucose_roll_mean_6h` — 24-step baseline anchor.
11. `sin_hour` — $\sin(2\pi \cdot \text{hour} / 24)$ circadian phase.
12. `cos_hour` — $\cos(2\pi \cdot \text{hour} / 24)$ circadian phase.
13. `is_night` — Binary nocturnal mask (23:00 to 06:00).
14. `insulin_basal` (Units) — Background basal delivery.
15. `insulin_bolus` (Units) — Acute meal/correction bolus dose.
16. `insulin_total` (Units) — Total exogenous insulin.
17. `iob` (Units) — Exponential pharmacokinetic active Insulin-on-Board ($t_{1/2}=60\text{m}, \tau_{\text{act}}=5\text{h}$).
18. `carbs_estimate_g` (Grams) — Logged dietary carbohydrate amount.
19. `meal_flag` — Binary pulse indicator at meal onset.
20. `cob` (Grams) — Exponential pharmacodynamic Carbs-on-Board ($t_{\text{peak}}=45\text{m}, \tau_{\text{abs}}=4\text{h}$).
21. `insulin_cum_2h` (Units) — 8-step cumulative insulin load.
22. `carbs_cum_2h` (Grams) — 8-step cumulative carbohydrate load.

### C. Current 9 Static Clinical Biomarkers
1. `age` (Years), 2. `bmi` ($\text{kg/m}^2$), 3. `hba1c` ($\text{mmol/mol}$), 4. `glycated_albumin` ($\%$), 5. `fasting_glucose` ($\text{mg/dL}$), 6. `fasting_c_peptide` ($\text{nmol/L}$), 7. `macrovascular_comp_count`, 8. `microvascular_comp_count`, 9. `is_t1dm` (Binary).

---

## 3. Multimodal Candidate Features Classification Matrix

Each candidate feature is categorized strictly into one of five feasibility levels:
* **Category 1:** Already Available in V1
* **Category 2:** Potentially Derivable from Existing Data
* **Category 3:** Requires New Public Longitudinal Dataset
* **Category 4:** Requires Real-World Wearable Data Collection
* **Category 5:** Not Currently Feasible / Scientifically Weak

| Modality Dimension | Specific Candidate Feature | Feasibility Category | Scientific Impact on Glucose Prediction | Feasibility Assessment & Rationale |
|---|---|:---:|:---:|---|
| **Nutrition** | **Carbohydrates (g)** | **Cat 1 (In V1)** | **Critical (Highest)** | Primary exogenous driver of acute postprandial glycemic excursions. |
| **Nutrition** | **Carbs-on-Board (COB)** | **Cat 1 (In V1)** | **High** | Models gut transit and progressive gastric emptying over 4 hours. |
| **Nutrition** | **Protein (g)** | **Cat 2 / Cat 3** | **Moderate-High** | $50-60\%$ converted to glucose via slow hepatic gluconeogenesis over $3-6\text{ hours}$. In V1, can be estimated via NLP on `meal_text` or acquired from Nutrition5k / D1NAMO. |
| **Nutrition** | **Total Fat (g)** | **Cat 2 / Cat 3** | **Moderate-High** | Delays gastric emptying via cholecystokinin (CCK), flattening and prolonging postprandial glucose curves. Derivable via NLP from `meal_text` or Food Vision. |
| **Nutrition** | **Dietary Fiber (g)** | **Cat 2 / Cat 3** | **Moderate** | Soluble fiber reduces glycemic index (GI), attenuating glucose absorption rate $k_{\text{abs}}$. Derivable via USDA lookup. |
| **Nutrition** | **Saturated Fat (g)** | **Cat 5** | **Low (Acute)** | Chronic cardiovascular risk marker; acute glycemic kinetics are identical to total triglycerides/free fatty acids. Distinct modeling provides negligible acute predictive gain. |
| **Nutrition** | **Trans Fat (g)** | **Cat 5** | **Negligible (Acute)** | **Scientifically unjustified for 5h forecasting.** Trans fats do not have distinct acute 15-minute glycemic absorption pathways compared to total lipids. |
| **Nutrition** | **Meal Photographs** | **Cat 3 / Cat 4** | **Critical (Phase 6 Fix)** | Directly eliminates the $+51.2\%$ error spike on unlogged meals by automating carb/macro estimation from camera images. |
| **Activity** | **Step Count (15m)** | **Cat 3 / Cat 4** | **High** | Directly stimulates GLUT-4 non-insulin-mediated glucose uptake in skeletal muscle, dropping glucose. Requires accelerometer dataset (OhioT1DM). |
| **Activity** | **Exercise Intensity (METs)** | **Cat 3 / Cat 4** | **High** | Aerobic exercise lowers glucose; high-intensity anaerobic exercise causes transient hepatic glycogenolysis (glucose spike). |
| **Activity** | **Sedentary Time** | **Cat 3 / Cat 4** | **Moderate** | Prolonged sitting increases acute peripheral insulin resistance. |
| **Wearables** | **Heart Rate (bpm)** | **Cat 3 / Cat 4** | **Moderate-High** | Proxy for physical exertion and sympathetic nervous system activation. Available in OhioT1DM / Empatica / Zephyr. |
| **Wearables** | **Resting Heart Rate (RHR)** | **Cat 3 / Cat 4** | **Moderate** | Daily baseline biomarker indicating systemic inflammation, illness, or poor recovery. |
| **Wearables** | **Heart Rate Variability (HRV)** | **Cat 3 / Cat 4** | **Moderate** | High RMSSD reflects parasympathetic tone; depressed HRV reflects acute physiological stress or hypoglycemia onset. |
| **Sleep** | **Circadian Timing** | **Cat 1 (In V1)** | **Moderate** | Encoded via `sin_hour`, `cos_hour`, `is_night` in V1. |
| **Sleep** | **Sleep Duration & Stages** | **Cat 3 / Cat 4** | **Moderate** | Short sleep / fragmented REM induces acute morning cortisol surge (Dawn Phenomenon / morning insulin resistance). |
| **Stress** | **Acute Stress Proxy** | **Cat 3 / Cat 4** | **Low-Moderate** | Epinephrine/cortisol release stimulates hepatic glucose output. Challenging to measure reliably without continuous electrodermal activity (EDA/GSR). |

---

## 4. Fundamental Scientific Invariant: Zero Chimera Patients

> [!CAUTION]
> **STRICT RESEARCH INTEGRITY RULE:**  
> Under no circumstances will GlucoShield combine CGM data from one patient in Dataset v1.0 with step count or heart rate data from an unrelated patient in another dataset and present them as a single person.  
> Cross-patient signal stitching destroys physiological causality, invalidates mathematical ODE mass balances, and constitutes scientific fabrication. Any multimodal extension must rely on **co-recorded, synchronized telemetry from identical human subjects**.

---
*Certified for Phase 7A research planning.*
